ARCHIVES

Ibrutinib Produces 68% Overall Response Rate in Phase II Trial

This article is from The Cancer Letter archive.

Vol. 36 No. 1 | January 25, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: “Massive Reassessment” Of Centers Going On, Tim Talbot Believes; WHO Drops ICRB Service

December 9, 1977

HEW Secretary Tells Ethics Board To Take Up Issue of Compensation

September 28, 1979

Analyzing Tumor Tissue In Clinical Trials Can Improve Outcomes, RTOG Trial Finds

May 27, 2011

CMS Develops New Math of Medicare: Reimbursement Money for Outcomes Data.

February 4, 2005

Judge Rules FDA Can’t Enforce Pediatric Rule

October 25, 2002

DCBDC To Contract For CA Agents In Vaccine Testing

November 15, 1991